Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2012; 4(01): 017-023
DOI: 10.4103/0974-2727.98665
Original Article

Effect of Exercise Therapy on Lipid Parameters in Patients with End-Stage Renal Disease on Hemodialysis

Lorenzo Gordon
Kingston Public Hospital, North Street, Kingston, Jamaica
,
Donovan A McGrowder
Department of Pathology, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica
,
Yeiny T Pena
Department of Medicine, May Pen Hospital, Clarendon, Jamaica
,
Elsa Cabrera
Department of Postgraduate Studies and Teaching, Hermanos Ameijeiras Hospital, Havana, Cuba
,
Marilyn Lawrence-Wright
Department of Medicine, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica
› Author Affiliations Source of Support: There is no competing financial or other interest in relation to this research
› Further Information
Also available at
  PDF Download Permissions and Reprints

ABSTRACT

Background: Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease in chronic kidney disease patients.

Aim: This study investigated the impact of Hatha yoga exercise on lipid parameters in patients with end-stage renal disease (ESRD) on hemodialysis.

Materials and Methods: This prospective randomized study consisted of 33 ESRD patients in the Hatha yoga exercise group that was matched with 35 ESRD patients in the control group. Serum total cholesterol, triglycerides, low-density lipoprotein (LDL)-cholesterol, and high-density lipoprotein (HDL)-cholesterol were determined at baseline (0 month) and after 4 months.

Results: Comparing values after 4 months versus baseline in the prehemodialysis Hatha yoga exercise group, there was found a significant decrease in total cholesterol from 5.126 ± 0.092 mmol/l to 4.891 ± 0.072 mmol/l (-4.58%; P = 0.0001), triglycerides from 2.699 ± 0.078 mmol/l to 2.530 ± 0.063 mmol/l (-6.26%; P = 0.0001), LDL-cholesterol from 2.729 ± 0.083 mmol/l to 2.420 ± 0.066 mmol/l (-11.32%; P = 0.0001), and total cholesterol/HDL-cholesterol ratio from 5.593 ± 0.119 mmol/l to 4.907 ± 0.116 mmol/l (-12.26%; P = 0.047). For patients in the Hatha yoga exercise group, 51.5% had normal total cholesterol at 0 month while 70.0% had normal total cholesterol (P <0.05)after 4 four months and 54.5% of patients had normal LDL-cholesterol at 0 month while 84.9% had normal LDL-cholesterol after 4 months (P <0.05).

Conclusion: These findings suggest that Hatha yoga exercise has preventive and beneficial effects and may be a safe therapeutic modality in ESRD patients.

Keywords

Cardiovascular - end-stage renal disease, - hatha yoga exercise - total cholesterol


Publication History

Article published online:
09 May 2020

© 2012.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • REFERENCES

  • 1 Junyent M, Martínez M, Borràs M, Coll B, Valdivielso JM, Vidal T, et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol 2010;11:14.
  • 2 Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9.
  • 3 Al Wakeel JS, Mitwalli AH, Al Mohaya S, Abu-Aisha H, Tarif N, Malik GH, et al. Morbidity and mortality in ESRD patients on dialysis. Saudi J Kidney Dis Transpl 2002;13:473-7.
  • 4 United States Renal Data System. USRDS (2000) Annual Data Report: Atlas of End-Stage Renal Disease in the United States (ed 12th Annual Report), Division of Kidney, Urologic and Hematological diseases. Bethesda, MD: National Institute of Diabetes and Digestive Kidney Diseases, National Institutes of Health; 2000.
  • 5 Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14(9 Suppl 4):S315-20.
  • 6 Liu J, Rosner MH. Lipid abnormalities associated with end-stage renal disease. Semin Dial 2006;19:32-40.
  • 7 Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005;99:S87-93.
  • 8 Pennell P, Leclercq B, Delahunty MI, Walters BA. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney diseases. Clin Nephrol 2006;66:336-47.
  • 9 Cressman MD, Heyka RJ, Paganini EP, O′Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992;86:475-82.
  • 10 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
  • 11 Barnea N, Drory Y, Iaina A, Lapidot G, Reisin E, Eliahou H, et al. Exercise tolerance in patients on chronic hemodialysis. Isr J Med Sci 1980;16:17-21.
  • 12 Moore G, Brinker K, Stray-Gundersen J, Mitchell J. Determinants of VO2 peak in patients with end-stage renal disease: on and off dialysis. Med Sci Sports Exerc 1993;25:18-23.
  • 13 Gutman RA, Stead WW, Robinson RR. Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981;304:309-13.
  • 14 Evans RW, Manninen DL, Garrison LP. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9.
  • 15 Painter P, Messer-Rahak D, Hanson P, Zimmerman SW, Glass NR. Exercise capacity in hemodialysis, CAPD, and renal transplant patients. Nephron 1986;42:47-51.
  • 16 Zabetakis PM, Gleim GW, Pasternack FL, Saraniti A, Nicholas JA, Michelis MF. Long-duration submaximal exercise conditioning in hemodialysis patients. Clin Nephrol 1982;18:17-22.
  • 17 Goldberg AP, Geltman EM, Hagberg JM, Gavin JR, Delmez JA, Carney RM, et al. Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int 1983;24 (Suppl 16):S303-9.
  • 18 Johansen KL. Exercise and chronic kidney disease: Current recommendations Sports Med 2005;35:485-99.
  • 19 Goldberg AP, Geltman EM, Gavin JR III. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron 1986;42:311-6.
  • 20 Mustata S, Chan C, Lai V, Miller JA. Impact of an exercise program on arterial stiffness and insulin resistance in hemodialysis patients. J Am Soc Nephrol 2004;15:2713-8.
  • 21 Kirkwood G, Rampes H, Tuffrey V, Richardson J, Pilkington K. Yoga for anxiety: a systematic review of the research evidence. Br J Sports Med 2005;39:884-91.
  • 22 Raub JA. Psychophysiologic effects of Hatha yoga on musculoskeletal and cardiopulmonary function: a literature review. J Altern Complement Med 2002;8:797-812.
  • 23 Kolasinski SL, Garfinkel M, Tsai AG, Matz W, Van Dyke A, Schumacher HR. Iyengar yoga for treating symptoms of osteoarthritis of the knees: A pilot study. J Altern Complement Med 2005;11:689-93.
  • 24 Yurtkuran M, Alp A, Yurtkuran M, Dilek K. A modified yoga-based exercise program in hemodialysis patients: a randomized controlled study. Complement Ther Med 2007;15:164-71.
  • 25 Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
  • 26 Burstein M, Scholnick HR, Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-95.
  • 27 Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-80.
  • 28 Friedewald Wi′, Levy RI, Fredrickson DS. Estimation of the concentrationof lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
  • 29 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
  • 30 Feinstein A. Clinical epidemiology, the architecture of clinical research. 1st ed. Philadelphia: WB Saunders Co; 1985.
  • 31 Chan MK. Lipid metabolism in renal failure. Clin Biochem 1990;23;61-65.
  • 32 Bijlani RL, Vempati RP, Yadav RK, Ray RB, Gupta V, Sharma R, et al. A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus. J Altern Complement Med 2005;11:267-74.
  • 33 Khare KC, Rai S. Study of lipid profile in post myocardial infarction subjects following yogic life style intervention. The Indian Practitioner 2002;55:369-73.
  • 34 Mahajan AS, Reddy KS, Sachdeva U. Lipid profile of coronary risk subjects following yogic lifestyle intervention. Indian Heart J 1999;51:37-40.
  • 35 Yogendra J, Yogendra HJ, Ambardekar S, et al. Beneficial effects of yoga lifestyle on reversibility of ischaemic heart disease: caring heart project of International Board of Yoga. J Assoc Physicians India 2004;52:283-9.
  • 36 Assman G, Schulte H. Relation of high density lipoprotein cholesterols and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular munster study. Am J Cardiol 1992;70:733-7.
  • 37 Hokanson JE, Austin MA. Plasma triglyceride level is a risck factor for cardiovascular disease independent of high density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
  • 38 Alsaran K, Sabry A, Shaheen N. Is non-fasting non-high-density lipoprotein cholesterol adequate for lipid management in Saudi hemodialysis patients? J Nephrology and Renal Transplantation 2009;2:1-17.
  • 39 Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002;13:1918-27.
  • 40 Ibels LS, Simons LA, King JD. Plasma post heparin lipolytic activity and triglyceride clearance in uremic hemodialysis patients and renal allograft recipients. Lab Clin Med 1976;87:648-58.
  • 41 Sharma BK, Jindal SK, Rana DS. Absence of hyperlipidemia in patients of chronic renal failure in Chandigarh. Indian J Med Res 1980;72:461-64.
  • 42 Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, Lhotta K, et al. Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. J Am Soc Nephrol 2002;13:461-9.
  • 43 Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991;57:401-10.
  • 44 Verdich C, Toubro S, Buemann B, Holst JJ, Bülow J, Simonsen L, et al. Leptin levels are associated with fat oxidation and dietary-induced weight loss in obesity. Obes Res 2001;9:452-61.
  • 45 Jequier E, Tappy L. Regulation of body weight in humans. Physiol Rev 1999;79:451-80.
  • 46 Heuck CC, Ritz E. Hyperlipoproteinemia in renal insufficiency. Nephron 1980;25:1-7.
  • 47 Querfeld U. Disturbances of lipid metabolism in children with chronic renal failure. Pediatric Nephrology 1993;7:749-57.